Tokai Raises $23 Million In Series D Financing
This article was originally published in The Pink Sheet Daily
Executive Summary
The start up's focus is on a highly competitive indication, refractory prostate cancer, but its ability to raise money could be tied to the novelty of its lead compound
You may also be interested in...
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
FDA’s speedy approval of Johnson & Johnson’s Zytiga (abiraterone) on April 28 – two months before the PDUFA date – paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space.
Prostate Cancer Market Snapshot: More Than Provenge
The launch of two drugs for metastatic prostate cancer this year – Dendreon Corp.'s Provenge (sipuleucel-T) and Sanofi-Aventis SA's Jevtana (cabazitaxel) – is shining a spotlight on an area of oncology that for many years was marked by a dearth of new treatment options.
Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK
Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.